Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups

Pharmacogenetics

Volumn 13, Issue 8, 2003, Pages 461-472

  Lee, Su Jun ^a   Usmani, Khawja A ^b   Chanas, Brian ^a   Ghanayem, Burhan ^a   Xi, Tina ^c   Hodgson, Ernest ^b   Mohrenweiser, Harvey W ^c   Goldstein, Joyce A ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

Author keywords

cDNA expression system; CYP3A5; CYP3A5 polymorphisms; Drug metabolism; Human; SNP

Indexed keywords

CYTOCHROME P450 3A5; NIFEDIPINE; TESTOSTERONE DERIVATIVE;

AFRICA; ARTICLE; ASIAN; CAUCASIAN; CONTROLLED STUDY; ESCHERICHIA COLI; ETHNIC GROUP; GENETIC VARIABILITY; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PURIFICATION; RACE; SINGLE NUCLEOTIDE POLYMORPHISM; SITE DIRECTED MUTAGENESIS;

ALLELES; BASE SEQUENCE; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; DNA, COMPLEMENTARY; ESCHERICHIA COLI; ETHNIC GROUPS; HUMANS; MUTAGENESIS, SITE-DIRECTED; NIFEDIPINE; POLYMORPHISM, SINGLE NUCLEOTIDE; TESTOSTERONE;

ESCHERICHIA COLI;

EID: 0041881985     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200308000-00004     Document Type: Article

References (47)

1. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998; 38:389-430.
2. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286:487-491.
3. Gellner K, Eiselt R, Hustert E, Arnold H, Koch I, Haberl M, et al. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 2001; 11:111-121.
4. Wrighton SA, Ring BJ, Watkins PB, Vandenbranden M. Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol Pharmacol 1989; 36:97-105.
5. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genomic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 207:383-391.
6. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P4503A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinogen 1995; 13:129-134.
7. Bensoussan C, Delaforge M, Mansuy D. Particular ability of cytochromeP450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs. Biochem Pharmacol 1995; 49:591-602.
8. Fukuda K, Ohta T, Oshima Y, Ohashi N, Yoshikawa M, Yamazoe Y. Specific CYP3A4 inhibitors in grapefruit juice: Furocoumarin dimmers as components of drug interaction. Pharmacogenetics 1997; 7:391-396.
9. Collins FS, Brooks LD, Chakravarti. A DNA polymorphism discovery resource for research on human genetic variation. Genome Res 1998; 8:1229-1231.
10. Evans WE, Johnson JA. Pharmacogenomics: The inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2001; 2:9-39.
11. Waxman DJ, Attosano C, Guengerich FP, Lapenson DP. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6β-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys 1988; 263:424-436.
12. Coombes RC, Goss P, Dowsett M, Gazet JC, Brodie AMH. 4-Hydroxyandrostenedione treatment of postmenopausal patients with advanced breast cancer. Lancet 1984; 2:1237-1239.
13. Huang Z, Guengerich FP, Kaminsky LS. 16α-Hydroxylation of estrone by human cytochrome P4503A4/5. Carcinogenesis 1998; 19:867-872.
14. Shen MR, Jones IM, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 1998; 58:604-608.
15. Barnes HJ, Arlotto MP, Waterman MR. Expression and enzymatic activity of recombinant cytochrome P450 17α-hydroxylase in Escherichia coli. Proc Natl Acad Sci U S A 1991; 88:5597-5601.
16. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. J Biol Chem 1964; 239:2379-2385.
17. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ. Characterization of rat and human liver microsomal cytochrome P450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1986; 261:5051-5060.
18. Dai D, Tang J, Rose R, Hodgson E, Bienstock RJ, Mohrenweiser HW, Goldstein JA. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 2001; 299:825-831.
19. Distlerath LM, Reilly PEB, Martin MV, Davis GG, Wilkinson GR, Guengerich FP. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1985; 260:9057-9067.
20. Knodell RG, Hall SD, Wilkinson GR, Guengerich FP. Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. J Pharmacol Exp Ther 1987; 241:1112-1118.
21. Domanski TL, Liu J, Harlow GR, Halpert JR. Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: Role in steroid hydroxylase activity and α-naphthoflavone stimulation. Arch Biochem Biophys 1998; 350:223-232.
22. Imaoka S, Imai Y, Shimada T, Funae Y. Role of phospholipids in reconstituted cytochrome P450 3A form and mechanism of their activation of catalytic activity. Biochemistry 1992; 31:6063-6069.
23. Purdon MP, Lehman-McKeeman LD. Improved high-performance liquid chromatographic procedure for the separation and quantification of hydroxytestosterone metabolites. J Pharmacol Toxicol Methods 1997; 37:67-73.
24. Segal IH. Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems. John Wiley & Sons Inc., New York; 1975.
25. He YA, Roussel F, Halpert JR. Analysis of homotropic and heterotropic cooperativity of diazepam oxidation by CYP3A4 using site-directed mutagenesis and kinetic modeling. Arch Biochem Biophys 2003; 409:92-101.
26. Houston JB, Kenworthy KE. In vitro-in vivo scaling of CYP kinetic data not consistent with classical Michaelis-Menten model Drug Metab Dispos 2000; 28:246-254.
27. Antonarakis SE, and the Nomenclature Working Group. Recommendations for a Nomenclature System for Human Gene Mutations. Hum Mutat 1998; 11:1-3.
28. Hustert E, Haberl M, Burk O, Wolbold R, He YO, Klein K, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11:773-779.
29. Kagawa N and Cao O. Osmotic stress induced by carbohydrates enhances expression of foreign proteins in Escherichia coli. Arch Biochem Biophys 2001; 393:290-296.
30. McLoad HL, Evans WE. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 2001; 41:101-121.
31. Sachidananandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001; 409:928-933.
32. Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002; 12:121-132.
33. Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet 1999; 22:231-238.
34. Lin YS, Dewling ALS, Quigley SD, Farin FM, Zhang J, Lamba J, et al. Coregulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002; 62:162-172.
35. Peng SS, Chen CY, Shyu AB. Functional characterization of a non-AUUUAAU-rich element from the c-jun proto-oncogene mRNA: evidence for a novel class of AU-rich elements. Mol Cell Biol 1996; 16:1490-1499.
36. Gonzalez CI, Bhattacharya A, Wang W, Peltz SW. Nonsense-mediated mRNA decay in Saccharomyces cerevisiae. Gene 2001; 274:15-25.
37. Hentze MW, Kuhn LC. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc Natl Acad Sci U S A 1996; 93:8175-8182.
38. Cascorbi I, Brockmoller J, Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 1996; 86:4965-4969.
39. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988; 331:442-446.
40. Miller MS, McCarver DG, Bell DA, Eaton DL, Goldstein JA. Genetic polymorphisms in human drug metabolic enzymes. Fundam Appl Toxicol 1997; 40:1-14.
41. Gillam EMG, Guo ZY, Ueng YF, Yamazaki H, Cock I, Reilly PEB, et al. Expression of cytochrome-P450-3A5 in Escherichia coli: effects of 5′ modification, purification, spectral characterization, reconstitution conditions, and activities. Arch Biochem Biophys 1995; 317:374-384.
42. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 2002; 30:883-891.
43. Jounaïdi Y, Hyrailles V, Gervot L, Maurel P. Detection of a CYP3A5 allelic variant: A candidate for the polymorphic expression of the protein? Biochem Biophys Res Commun 1996; 221:466-470.
44. Chou FC, Tzeng SJ, Huang JD. Genetic polymorphism of cytochrome P450 3A5 in Chinese. Drug Metab Dispos 2001; 29:1205-1209.
45. Black SD. Membrane topology of the mammalian P450 cytochromes. FASEB J 1992; 6:680-685.
46. Hosea NA, Miller GP, Guengerich FP. Elucidation of distinct ligand binding sites for cytochrome P450 3A4. Biochemistry 2000; 39:5909-5939.
47. Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, et al. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem 1989; 264:10388-10395.